Skip to main content

Advertisement

SpringerLink
Log in

Serum vitronectin levels in patients with Behçet’s disease

  • Original Research Paper
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Background/aims

To determine serum vitronectin levels in Behçet patients with and without ocular involvement, and to evaluate the relationship between vitronectin concentrations and clinical manifestations of Behçet’s disease (BD).

Methods

Sixty-five patients with BD and 21 control subjects were included. All patients were queried for the clinical manifestations of BD. Serum vitronectin concentrations were determined by using in vitro enzyme immunoassay kits.

Results

Serum vitronectin levels between the patients and the control subjects were not different. There was no statistically significant difference between vitronectin levels in Behçet patients with and without ocular involvement. No correlation was found between vitronectin concentrations and clinical manifestations.

Conclusion

This is the first study evaluating vitronectin levels in Behçet patients. Further studies involving larger numbers of subjects would be useful to improve our understanding of the functions of vitronectin in BD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ekmekci H, Ekmekci OB, Sonmez H, Ozturk Z, Domanic N, Kokoglu E. Evaluation of fibronectin, vitronectin, and leptin levels in coronary artery disease: impacts on thrombosis and thrombolysis. Clin Appl Thromb Hemost. 2005;11:63–70.

    Article  PubMed  CAS  Google Scholar 

  2. Ekmekci OB, Ekmekci H. Vitronectin in atherosclerotic disease. Clin Chim Acta. 2006;368:77–83.

    Article  PubMed  CAS  Google Scholar 

  3. Reheman A, Gross P, Yang H, Chen P, Allen D, Leytin V, Freedman J, Ni H. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost. 2005;3:875–83.

    Article  PubMed  CAS  Google Scholar 

  4. Ekmekci H, Sonmez H, Ekmekci OB, Ozturk Z, Domanic N, Kokoglu E. Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis. 2002;14:221–5.

    Article  PubMed  CAS  Google Scholar 

  5. Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood. 1999;93:1825–30.

    PubMed  CAS  Google Scholar 

  6. Koschnick S, Konstantinides S, Schafer K, Crain K, Loskutoff DJ. Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin. J Thromb Haemost. 2005;3:2290–5.

    Article  PubMed  CAS  Google Scholar 

  7. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation. 2001;103:576–83.

    Article  PubMed  CAS  Google Scholar 

  8. Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JI. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem. 2000;275:19788–94.

    Article  PubMed  CAS  Google Scholar 

  9. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol. 2003;10:541–4.

    Article  PubMed  CAS  Google Scholar 

  10. Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res. 1998;89:1–21.

    Article  PubMed  CAS  Google Scholar 

  11. Newall F, Johnston L, Ignjatovic V, Summerhayes R, Monagle P. Age-related reference ranges for two heparin-binding proteins: vitronectin and platelet factor 4. Int J Lab Hematol. 2009;31:683–7.

    Article  PubMed  CAS  Google Scholar 

  12. Mohri H, Ohkubo T. How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol. 1991;96:605–9.

    PubMed  CAS  Google Scholar 

  13. Antonov AS, Antonova GN, Munn DH, Mivechi N, Lucas R, Catravas JD, Verin AD. αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt-dependent NF-κB activation. J Cell Physiol. 2011;226:469–76.

    Article  PubMed  CAS  Google Scholar 

  14. Li R, Ren M, Chen N, Luo M, Zhang Z, Wu J. Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions. PLoS One. 2012;7(5):e37195.

    Article  PubMed  CAS  Google Scholar 

  15. International Study Group for Behcet’s disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335:1078–80.

    Google Scholar 

  16. Citirik M, Haznedaroglu IC, Teberik K, Soykan E, Zilelioglu O. Basic parameters of thrombophilia in ocular Behcet disease with posterior segment involvement. Br J Ophthalmol. 2009;93:1382–6.

    Article  PubMed  CAS  Google Scholar 

  17. Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet’s disease: a systematic review. J Neurol. 2011;258:719–27.

    Article  PubMed  CAS  Google Scholar 

  18. Yasar NS, Salgur F, Cansu DU, Kasifoglu T, Korkmaz C. Combined thrombophilic factors increase the risk of recurrent thrombotic events in Behcet’s disease. Clin Rheumatol. 2010;29:1367–72.

    Article  PubMed  Google Scholar 

  19. Kiraz S, Ertenli I, Ozturk MA, Haznedaroglu IC, Celik I, Calguneri M. Pathological haemostasis and prothrombotic state in Behcet’s disease. Thromb Res. 2002;105:125–33.

    Article  PubMed  CAS  Google Scholar 

  20. Krupa B, Cimaz R, Ozen S, Fischbach M, Cochat P, Kone-Paut I. Pediatric Behcet’s disease and thromboses. J Rheumatol. 2011;38:387–90.

    Article  PubMed  Google Scholar 

  21. Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behcet’s disease. Am J Ophthalmol. 2004;137:850–7.

    Article  PubMed  CAS  Google Scholar 

  22. Donmez A, Aksu K, Aydın H, Keser G, Cagirgan S, Doganavsargil E, Tombuloglu M. The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behcet disease and their association with thrombosis. Thromb Res. 2010;126:207–10.

    Article  PubMed  CAS  Google Scholar 

  23. Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, Inal V, Aydın HH, Tombuloglu M, Doganavsargil E. Thrombin activatable fibrinolysis inhibitor in Behcet’s disease. Thromb Res. 2005;115:287–92.

    Article  PubMed  CAS  Google Scholar 

  24. Citirik M, Berker N, Songur MS, Ozkan SS, Zilelioglu O. Ocular manifestations of late-onset Behcet disease. Ophthalmologica. 2011;225:21–6.

    Article  PubMed  Google Scholar 

  25. Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Sadeghi Abdollahi B. How to deal with Behcet’s disease in daily practice. Int J Rheum Dis. 2010;13:105–16.

    Article  PubMed  Google Scholar 

  26. Birengel S, Yalcindag FN, Yalcindag A, Sahli E, Batioglu F. Urokinase plasminogen activator receptor levels in Behcet’s disease. Thromb Res. 2011;128:274–6.

    Article  PubMed  CAS  Google Scholar 

  27. Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC. Vascular involvement in Behcet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37–43.

    Article  PubMed  CAS  Google Scholar 

  28. Akar S, Ozcan MA, Ates H, Gurler O, Alacacioglu I, Ozsan GH, Akkoc N, Ozkan S, Demirkan F, Onen F. Circulated activated platelets and increased platelet reactivity in patients with Behcet’s disease. Clin Appl Thromb Hemost. 2006;12:451–7.

    Article  PubMed  CAS  Google Scholar 

  29. Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol. 2009;21:41–6.

    Article  PubMed  Google Scholar 

  30. Acikgoz N, Karincaoglu Y, Ermis N, Yagmur J, Atas H, Kurtoglu E, Cansel M, Barutcu I, Pekdemir H, Ozdemir R. Increased mean platelet volume in Behcet’s disease with thrombotic tendency. Tohoku J Exp Med. 2010;221:119–23.

    Article  PubMed  CAS  Google Scholar 

  31. Mogulkoc N, Burgess MI, Bishop PW. Intracardiac thrombus in Behcet’s disease: a systematic review. Chest. 2000;118:479–87.

    Article  PubMed  CAS  Google Scholar 

  32. Cekmen M, Evereklioglu C, Er H, Inaloz HS, Doganay S, Turkoz Y, Ozerol IH. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet’s syndrome. Int J Dermatol. 2003;42:870–5.

    Article  PubMed  CAS  Google Scholar 

  33. Ricart JM, Ramon LA, Vaya A, Espana F, Santaolaria ML, Todoli J, Castello R, Fontcuberta J, Estelles A. Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br J Haematol. 2008;141:716–9.

    Article  PubMed  CAS  Google Scholar 

  34. Yalcindag FN, Batioglu F, Ozdemir O, Cansizoglu E, Egin Y, Akar N. Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2008;246:1603–8.

    Article  PubMed  CAS  Google Scholar 

  35. Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90:125–32.

    Article  Google Scholar 

  36. Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Faridar A, Ashofteh F, Sadeghi Abdollahi B. Behcet’s disease: from east to west. Clin Rheumatol. 2010;29:823–33.

    Article  PubMed  Google Scholar 

  37. Atmaca L, Boyvat A, Yalcindag FN, Atmaca-Sonmez P, Gurler A. Behcet disease in children. Ocul Immunol Inflamm. 2011;19:103–7.

    Article  PubMed  Google Scholar 

  38. Guermazi S, Hamza M, Dellagi K. Protein S deficiency and antibodies to protein S in patients with Behcet’s disease. Thromb Res. 1997;86:197–204.

    Article  PubMed  CAS  Google Scholar 

  39. Navarro S, Ricart JM, Medina P, Vaya A, Villa P, Todoli J, Estelles A, Mico ML, Aznar J, Espana F. Activated protein C levels in Behcet’s disease and risk of venous thrombosis. Br J Haematol. 2004;126:550–6.

    Article  PubMed  CAS  Google Scholar 

  40. Chafa O, Fischer AM, Meriane F, Chellali T, Sternberg C, Otmani F, Benebadji M. Behcet syndrome associated with protein S deficiency. Thromb Haemost. 1992;67:1–3.

    PubMed  CAS  Google Scholar 

  41. Lenk N, Ozet G, Alli N, Coban O, Erbasi S. Protein C and protein S activities in Behcet’s disease as risk factors of thrombosis. Int J Dermatol. 1998;37:124–5.

    Article  PubMed  CAS  Google Scholar 

  42. Nalcaci M, Pekcelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behcet’s disease. J Int Med Res. 1998;26:206–8.

    PubMed  CAS  Google Scholar 

  43. Ozturk MA, Ertenli I, Kiraz S, Haznedaroglu IC, Celik I, Kirazli S, Calguneri M. Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behcet’s disease. Rheumatol Int. 2004;24:98–102.

    Article  PubMed  Google Scholar 

  44. Derer W, Barnathan ES, Safak E, Agarwal P, Heidecke H, Möckel M, Gross M, Ozcelik C, Dietz R, Dechend R. Vitronectin concentrations predict risk in patients undergoing coronary stenting. Circ Cardiovasc Interv. 2009;2:14–9.

    Article  PubMed  Google Scholar 

  45. Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, Schomig A. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation. 1997;96:1809–18.

    Article  PubMed  CAS  Google Scholar 

  46. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18:882–92.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Ankara University Research Fund (Project no: 10B3330022). The funding source had no involvement in study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the article for publication. We gratefully acknowledge the excellent technical assistance of Fatoş Özyalçın, Emine Özyurt and Meral Tiryaki.

Conflict of interest

None of the authors have any actual or potential conflict of interest, including any financial, personal or other relationships with any of the products or providers within 3 years of beginning the study.

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

    Ali Yalçındağ & Namık Delibaş

  2. Department of Ophthalmology, Ankara University Faculty of Medicine, Mamak Cad. Dikimevi, Ankara, 06100, Turkey

    Aslıhan Uzun & F. Nilüfer Yalçındağ

Authors
  1. Ali Yalçındağ
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aslıhan Uzun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Nilüfer Yalçındağ
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Namık Delibaş
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aslıhan Uzun.

Additional information

Responsible Editor: Graham Wallace

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yalçındağ, A., Uzun, A., Nilüfer Yalçındağ, F. et al. Serum vitronectin levels in patients with Behçet’s disease. Inflamm. Res. 61, 1241–1246 (2012). https://doi.org/10.1007/s00011-012-0521-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-012-0521-z

Keywords

Search

Navigation